A pharmaceutical company, Vantage Hemp Co., announced it recently submitted two Drug Master Files (DMFs) to the Food and Drug Administration.
Colorado-based Vantage Hemp Co. announced today that it submitted a Drug Master File (DMF) for its cannabidiol (CBD) isolate to the Food and Drug Administration (FDA), having submitted one for its CBD distillate in 2022 (1).
“Drug master files (DMFs) are submissions to FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products,” stated the FDA website (2).
“Drug Master Files move the CBD industry forward with professionalism and legitimacy,” said Deepank Utkhede, Vantage’s Chief Operating Officer (1). “This is a significant milestone for our company. We believe that a commitment to consistency, quality, and cGMP compliance will help pave the way for greater regulatory clarity in the industry.”
With large-scale extraction facilities, Vantage Hemp Co. reportedly produces current good manufacturing practice (cGMP)-compliant CBD extracts including full-spectrum oil, distillate, and isolate.
References
Medical Cannabis Campaigning with Americans for Safe Access
September 4th 2024As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.